Additional Relevant Details Initially, The Phase 2 study by GlobalImmune of its drug GI-6301 on patients with chordoma with radiation treatment is expected to reach primary completion date in March 2017.  The study's primary endpoint is to measure the "difference in overall response rate among patients with Chordoma who are treated with radiation plus placebo vs. radiation plus vaccine."

It is now expected in March 2019.